戻る
Cabaletta Bio Inc (CABA)価格
CABA 株価推移チャート
CABA 収入
Cabaletta Bio Inc
$2.44
-2.78%
$-0.06
終値： Feb 09, 16:00:00 GMT-5
$2.43
-0.4%
$0
アフターマーケット：Feb 09, 19:11:52 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-10-27
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
CABAの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Cabaletta Bio Inc CABAの前四半期の収益はどうでしたか？
Cabaletta Bio Incの収益見積もりはいくらですか？
Cabaletta Bio Incの収益品質スコアはどれくらいですか？
Cabaletta Bio Incはいつ収益を報告しますか？
Cabaletta Bio Incの予想収益はいくらですか？
Cabaletta Bio Incは収益予想を上回りましたか？
主要データ
前終値
$2.51
始値
$2.5
当日レンジ
$2.41 - $2.51
52週レンジ
$0.986 - $3.67
取引高
1.8M
平均取引高
2.9M
1株当たり利益(TTM)
-2.51
配当利回り
--
時価総額
$233.9M
CABAとは何ですか？
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.